Häkkinen SH - Search Results

1

Influence of domestic processing and storage on flavonol contents in berries.

Häkkinen SH, Kärenlampi SO, Mykkänen HM, Törrönen AR. Häkkinen SH, et al. J Agric Food Chem. 2000 Jul;48(7):2960-5. doi: 10.1021/jf991274c. J Agric Food Chem. 2000. PMID: 11032486

2

Content of the flavonols quercetin, myricetin, and kaempferol in 25 edible berries.

Häkkinen SH, Kärenlampi SO, Heinonen IM, Mykkänen HM, Törrönen AR. Häkkinen SH, et al. J Agric Food Chem. 1999 Jun;47(6):2274-9. doi: 10.1021/jf9811065. J Agric Food Chem. 1999. PMID: 10794622

3

Flavonoids and phenolic acids in selected berries.

Törrönen R, Häkkinen S, Kärenlampi S, Mykkänen H. Törrönen R, et al. Cancer Lett. 1997 Mar 19;114(1-2):191-2. doi: 10.1016/s0304-3835(97)04660-0. Cancer Lett. 1997. PMID: 9103289 No abstract available.

4

High-performance liquid chromatography with electrospray ionization mass spectrometry and diode array ultraviolet detection in the identification of flavonol aglycones and glycosides in berries.

Häkkinen S, Auriola S. Häkkinen S, et al. J Chromatogr A. 1998 Dec 31;829(1-2):91-100. doi: 10.1016/s0021-9673(98)00756-0. J Chromatogr A. 1998. PMID: 9923078

5

Intake of flavonols and flavones and risk of coronary heart disease in male smokers.

Hirvonen T, Pietinen P, Virtanen M, Ovaskainen ML, Häkkinen S, Albanes D, Virtamo J. Hirvonen T, et al. Epidemiology. 2001 Jan;12(1):62-7. doi: 10.1097/00001648-200101000-00011. Epidemiology. 2001. PMID: 11138821

6

Quercetin intake and the incidence of cerebrovascular disease.

Knekt P, Isotupa S, Rissanen H, Heliövaara M, Järvinen R, Häkkinen S, Aromaa A, Reunanen A. Knekt P, et al. Eur J Clin Nutr. 2000 May;54(5):415-7. doi: 10.1038/sj.ejcn.1600974. Eur J Clin Nutr. 2000. PMID: 10822289

7

Incorporation of cancellous bone into a diaphyseal defect of the radius in growing rabbits: tube-shaped versus homogeneous grafts.

Langenskiöld A, Hakkinen S, Ylinen P. Langenskiöld A, et al. J Pediatr Orthop. 1996 Mar-Apr;16(2):237-42. doi: 10.1097/00004694-199603000-00020. J Pediatr Orthop. 1996. PMID: 8742292

8

Effect of severe renal failure and haemodialysis on the pharmacokinetics of levosimendan and its metabolites.

Puttonen J, Kantele S, Kivikko M, Häkkinen S, Harjola VP, Koskinen P, Pentikäinen PJ. Puttonen J, et al. Clin Pharmacokinet. 2007;46(3):235-46. doi: 10.2165/00003088-200746030-00004. Clin Pharmacokinet. 2007. PMID: 17328582 Clinical Trial.

9

Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.

Puttonen J, Kantele S, Ruck A, Ramela M, Häkkinen S, Kivikko M, Pentikäinen PJ. Puttonen J, et al. J Clin Pharmacol. 2008 Apr;48(4):445-54. doi: 10.1177/0091270007313390. Epub 2008 Feb 26. J Clin Pharmacol. 2008. PMID: 18303124 Clinical Trial.

10

Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men.

Puttonen J, Laine T, Ramela M, Häkkinen S, Zhang W, Pradhan R, Pentikäinen P, Koskinen M. Puttonen J, et al. Eur J Pharm Sci. 2007 Dec;32(4-5):271-7. doi: 10.1016/j.ejps.2007.08.003. Epub 2007 Aug 10. Eur J Pharm Sci. 2007. PMID: 17888637 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results